Drug intelligence / Profile preview

NSC-743380

Development stage
Preclinical
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Small Molecules
Administration
Oral, Intraperitoneal
01

Overview

NSC-743380 (also known as oncrasin-72) is a small molecule indole-3-carbinol analog with potent preclinical anticancer activity. Originally identified through synthetic lethality screening against KRAS-mutant cell lines, its mechanism of action involves the inhibition of the JAK2/STAT3 signaling pathway and the suppression of RNA polymerase II C-terminal domain phosphorylation, which leads to the inhibition of transcription and translation. It has also been shown to rapidly activate Tyrosine kinase 2 (Tyk2), p38, and JNK, ultimately inducing caspase-dependent apoptosis. NSC-743380 has demonstrated efficacy in various xenograft models, including renal and lung cancers, and is noted for its oral bioavailability. It is particularly effective in cells expressing SULT1A1.

Other names
1-[(3-chlorophenyl)-methyl]-1H-indole-3-carbinol
02

Targets

Pol II (RNA polymerase II elongation factors)SULT1A1 (Sulfotransferase 1A1)JAK2 (Janus kinase 2)JNK (Mitogen-activated protein kinase kinase kinase family)STAT3 (Signal Transducer and Activator of Transcription 3)TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on NSC-743380.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSC-743380.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call